PMID- 37345608
OWN - NLM
STAT- MEDLINE
DCOM- 20230623
LR  - 20230625
IS  - 1842-1121 (Electronic)
IS  - 1841-8724 (Linking)
VI  - 32
IP  - 2
DP  - 2023 Jun 22
TI  - Transarterial Chemoembolization plus Apatinib with or without Camrelizumab for 
      the Treatment of Advanced HBV-related Hepatocellular Carcinoma.
PG  - 182-189
LID - 10.15403/jgld-4667 [doi]
AB  - AIMS: To compare the effectiveness and safety of transarterial chemoembolization 
      (TACE) combined with apatinib plus camrelizumab (TACE+AC) versus TACE combined 
      with apatinib alone (TACE+A) for patients with advanced HBV-related 
      hepatocellular carcinoma (HBV-HCC). METHODS: The clinical data of patients with 
      HBV-HCC who received either TACE+AC or TACE+A treatment were retrospectively 
      analyzed. Overall survival (OS), progression-free survival (PFS), objective 
      response rate (ORR), disease control rate (DCR), and adverse events (AEs) were 
      compared between the two groups. Multivariate Cox proportional hazards model 
      regression analysis was used to identify the independent prognostic factors of 
      OS. RESULTS: Between March 2019 to January 2022, 76 patients were assigned to the 
      TACE+AC group (n = 37) and the TACE+A group (n=39). The median OS and PFS in the 
      TACE+AC group were significantly longer than those in the TACE+A group (OS, 15.4 
      vs. 11.3 months; p=0.008; PFS, 7.4 vs. 5.1 months; p=0.001) and the ORR and DCR 
      in the TACE + AC group were significantly greater than those in the TACE+A group 
      (ORR, 43.2% vs. 20.5%; p=0.033; DCR, 67.6% vs. 43.6%; p=0.036). There was no 
      significant difference in the incidence of grade >/=3 AEs between the two groups 
      (p=0.483). Multivariate regression analysis identified the treatment modalities, 
      AFP level, and extrahepatic metastasis as independent prognostic factors 
      (p<0.05). CONCLUSION: TACE+AC significantly improved the clinical outcomes of 
      patients with HBV-HCC and elicited relatively controllable AEs.
FAU - Liu, Haonan
AU  - Liu H
AD  - Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, 
      Jiangsu, China. . why974300@163.com.
FAU - Yu, Qianqian
AU  - Yu Q
AD  - Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, 
      Jiangsu, China. 913472366@qq.com.
FAU - Gu, Ting
AU  - Gu T
AD  - Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, 
      Jiangsu, China. 1257422312@qq.com.
FAU - Qu, Pengfei
AU  - Qu P
AD  - Department of Gastroenterology, The Second Affiliated Hospital of Xuzhou Medical 
      University, Jiangsu, China. qupengfei1678@163.com.
FAU - Ma, Xiao
AU  - Ma X
AD  - Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, 
      Jiangsu, China. 1764112529@qq.com.
FAU - Zhou, Shuang
AU  - Zhou S
AD  - Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, 
      Jiangsu, China. 1500972766@qq.com.
FAU - Lu, Tong
AU  - Lu T
AD  - Department of Gastroenterology, The Affiliated Hospital of Xuzhou Medical 
      University, Jiangsu, China. lutong334@163.com.
FAU - Pan, Di
AU  - Pan D
AD  - Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, 
      Jiangsu, China. pd666@163.com.
FAU - Han, Zhengxiang
AU  - Han Z
AD  - Department of Oncology, The Affiliated Hospital of Xuzhou Medical University, 
      Jiangsu, China. cnhzxyq@163.com.
LA  - eng
PT  - Journal Article
DEP - 20230622
PL  - Romania
TA  - J Gastrointestin Liver Dis
JT  - Journal of gastrointestinal and liver diseases : JGLD
JID - 101272825
RN  - 5S371K6132 (apatinib)
RN  - 73096E137E (camrelizumab)
SB  - IM
MH  - Humans
MH  - *Carcinoma, Hepatocellular/pathology
MH  - *Liver Neoplasms/pathology
MH  - Hepatitis B virus
MH  - Retrospective Studies
MH  - *Chemoembolization, Therapeutic/adverse effects
MH  - Combined Modality Therapy
EDAT- 2023/06/22 06:42
MHDA- 2023/06/23 06:42
CRDT- 2023/06/22 05:43
PHST- 2022/10/17 00:00 [received]
PHST- 2023/03/19 00:00 [accepted]
PHST- 2023/06/23 06:42 [medline]
PHST- 2023/06/22 06:42 [pubmed]
PHST- 2023/06/22 05:43 [entrez]
AID - 10.15403/jgld-4667 [doi]
PST - epublish
SO  - J Gastrointestin Liver Dis. 2023 Jun 22;32(2):182-189. doi: 10.15403/jgld-4667.